3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Investor Presentation (November 2025)
47 slides from 3b Blackbio Dx's investor presentation, Nov 13, 2025
Slide 1: Covering letter to BSE
(Formerly – Kilpest India Limited) Ref. No.P-66/2025-26/57 November 13, 2025 The Relationship Manager, Department of Corporate Relations BSE Limited, P.J. Towers, Dalal Street Fort, MUMBAI – 400 001 Dear Sir/Madam, Please find the enclosed herewith Investor’s Presentation / Company Update of Agroche
Slide 2: Investor Presentation November 2025
Since 1972 Investor Presentation November, 2025
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (the “Presentation”), which has been prepared by 3B BlackBio Dx Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securiti
Slide 4: Financial Highlights – H1 2025-26
Financial Highlights – H1 2025-26 5,613.67 H1 2024-25 4,858.10 H1 2025-26 3,366.30 3,548.37 2,616.04 2,768.21 32.31 30.54 Revenue from Operations PBT PAT EPS Consolidated H1 2024-25 H1 2025-26 Rs. In Lakh Revenue from Operations 4,858.10 5,613.67* Profit Before tax 3,366.30 3,548.37** Profit After t
Slide 5: Key Highlights – Agrochemicals Division
Key Highlights – Agrochemicals Division Main Thrust Area of R&D Development of novel formulations for agriculture and public health which are less harmful and cost effective. Performance monitoring of existing products/process. Improvement in existing products/process with a customer driven ap
Slide 6: Agrochemicals - Existing Products
Agrochemicals - Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 •
Slide 7: Selected as part of Select 200 Companies
3B BlackBio has been selected as a part of “Select 200 Companies” with the global business potential at DGEMS2023 held in Delhi on 27th October 2023 presented by Forbes India & D Globalist.
Slide 8: Highlights Molecular Diagnostics (MDx) Division
Highlights Molecular Diagnostics (MDx) Division H1 2025-26
Slide 9: Overview – MDx Division
Overview – MDx Division Founded: November 2010 | 15 years in molecular diagnostics Core Focus: Design, Development & Manufacture of Molecular Diagnostic Kits: qPCR Assays (TRUPCR ®) Lateral Flow Assays (TRURAPID ®) NGS Assays (TRUNGS ®) Product Portfolio: 120+ Molecular Diagnostic Assays
Slide 10: Overview – MDx Division
Overview – MDx Division Well Established PAN-India & Comprehensive Brand Global Presence Molecular Diagnostics Only company to have Product & customer support Well established molecular qPCR Assays, Lateral Flow access available to over 600 diagnostics (MDx) brand Tests and NGS assays labs / hospita
Slide 11: Vision, Mission & Values
Vision, Mission & Values Our Vision • To offer reliable, affordable and effective healthcare solutions to all by recognizing the great potential of biotechnology to effectively diagnose rare, chronic and severe illnesses. Our Mission • To design and develop molecular diagnostics products of superior
Slide 12: Our Journey
Our Journey 1 2 O O oO O 2011-2013 2014-2016 - Founded asa + Entry into Molecular i . Lifesciences company + Initiated R&D in Molecular Diagnostics Diagnostics with Launch of TRUPCR® MDx Kits in Infectious Diseases & Oncology Portfolio 2017-2018 Received FMPCCI Outstanding Achievement Award Received
Slide 13: Our Strategic Priorities
Our Strategic Priorities Market Penetration: Portfolio Expansion: We aim to boost sales with current Leveraging our R&D strengths, we customers and channel partners by continuously evolve our portfolio – with expanding the range of products within new assays in qPCR, Lateral flow their existing port
Slide 14: Growth Canvas
Sales in INR Millions Growth Canvas
Slide 15: MDx Business – Financials Highlights – H1 2025-26
MDx Business – Financials Highlights – H1 2025-26 5,038.89* 3,618.54 ** 4,151.99 3,387.70 H1 2024-25 H1 2025-26 H1 2024-25 H1 2025-26 Revenue from Operations H1 2024-25 EBITDA 3,530.09 H1 2025-26 2,747.35 Rs. In Lakh. 3,340.79 2,590.52 H1 2024-25 H1 2025-26 H1 2024-25 H1 2025-26 PBT PAT * In above n
Slide 16: Business Outlook – MDx (Q2/2025-26)
Business Outlook – MDx (Q2/2025-26) We closed Q2 2025-26 with INR 3042.83 Lakh* (Including COVID Sales of INR 10.23 Lakh) compared to INR 2457.55 Lakh in Q2 2024-25. This includes consolidated sales from TRUPCR Europe Limited, Manchester for INR 487.28 Lakh. In Q2 2025-26, we did export of INR 496.7
Slide 17: Business Outlook – MDx (FY 2025-26 – 3B India)
Business Outlook – MDx (FY 2025-26 – 3B India) Market Overview & Growth Outlook The Total Addressable Market (TAM) for Molecular Diagnostics (MDx) in India is estimated at approx. ₹350–450 Cr. We hold a 12%–15% market share, positioning us among the market leaders. The MDx industry is projecte
Slide 18: Business Outlook – MDx (FY 2025-26 – 3B India)
Business Outlook – MDx (FY 2025-26 – 3B India) The company operates through three primary sales models in India: a) Tender Sales: This accounts for approximately 5%-7% of the total sales and it depends on type of tender, etc. b) Contractual / Reagent Rental Model: In this model, we provide molecular
Slide 19: Our Footprints in India
Our Footprints in India Head Office & Manufacturing Site Corporate Office – Delhi Sales Office - Mumbai Sales & Marketing Team Distributor Network
Slide 20: Our Global Presence
Our Global Presence We have widespread acceptance globally with our presence now in over 70 countries spanning across Europe, Middle East, APAC, LATAM, and North America (including the United States and Canada). Now we are expanding in Africa through strategic partnerships with channel partners.
Slide 21: Business Outlook – International
Business Outlook – International Global Expansion: Appointed new channel partners to strengthen international presence. Territorial Growth: Added customers in existing and new markets across Europe, Africa, and APAC. Regulatory Progress: Completed product registrations in several countries; on
Slide 22: Exports – Past Trend & Near Term Vision
Exports – Past Trend & Near Term Vision Our exports have grown substantially, as shown by the yearly figures below. This year, we project export growth of 20–25%. We now have presence across 70+ countries & 200+ customers. We have added a few countries in APAC and Africa post registration and tender
Slide 23: TRUPCR Europe Limited - Manchester Site
TRUPCR® Europe Limited - Manchester Site In Q2 FY 2025-26, TRUPCR® Europe Limited (TPE) sales have been a little low, due to the summer holiday time in Europe (August-September) and most of the work gets delayed. GBP 404,900 GBP 420,435 Q2 FY 2024-25 Q2 FY 2025-26 Although H1 Sales are up by ~12% as
Slide 24: TRUPCR Europe – Events & Conferences 2025-26
TRUPCR® Europe – Events & Conferences 2025-26 Like 2024-25, TPE has been participating extensively in the events and conferences. Since the start of this year, we have already participated in 4 major events:
Slide 25: TRUPCR Europe – Events & Conferences 2025-26
TRUPCR® Europe – Events & Conferences 2025-26 TPE will also be participating at the world’s largest medical trade fair, MEDICA, held annually in Düsseldorf, Germany, serves as a global marketplace for medical technology, diagnostics, and digital health, attracting exhibitors and visitors from over 7
Slide 26: Events & Conferences – INDIA
Events & Conferences – INDIA Our team was glad to be part of MICROCON Delhi 2025 (Oct 31 – Nov 2) – a premier event in clinical microbiology and infectious diseases with hands-on workshops, keynote addresses and networking sessions. We had strong footfall at our booth, great discussions with clinici
Slide 27: Events & Conferences – INDIA
Events & Conferences –INDIA Our team also participated in HAEMATOCON 2025 (Nov 6 – Nov 9), a focused platform to engage directly with haematologists, oncologists and lab specialists who work with complex blood disorders like leukemias, lymphomas and coagulation disorders. We showcased the TRUPCR® mo
Slide 28: Upcoming Events & Conferences - INDIA
Upcoming Events & Conferences - INDIA We will be participating in several important molecular biology and microbiology conferences in different parts of India during the next few months. These are premier events for India’s pathology and medical microbiology communities bringing clinicians, research
Slide 29: CORIS Bioconcept SRL, Belgium
CORIS Bioconcept SRL, Belgium Your company–3B (70%) along with its UK subsidiary–TPE (30%) have acquired all the shares of Coris Holding SRL, the parent company of Coris Bioconcept SRL (“Coris”) from Avacta Group Plc, London (a 30 years old manufacturer of Rapid Diagnostic Solutions) for an upfront
Slide 30: CORIS Bioconcept SRL, Belgium
CORIS Bioconcept SRL, Belgium Coris’ product portfolio comprises of rapid in-vitro diagnostic test kits, primarily focused on the antibiotic resistance markers (AMR). As part of this portfolio, the company offers a range of rapid lateral flow tests (LFT) designed to support early & accurate diagnosi
Slide 31: Our Certifications
Our Certifications ISO 13485:2016 & GMP Compliant manufacturing under the Medical Device QMS through BSI Licensed by CDSCO, Govt. Of India; equivalent to FDA, for our top-selling parameters in India Over 120 Parameters are CE-IVD marked The company is on track to achieve IVDR compliance by mid-FY 20
Slide 32: What Sets us Apart
What Sets us Apart Largest CE-IVD and Indian IVD Product Range with over 120 PCR assays developed and commercially available Large, expansive and highly loyal customer base spread across government & private hospitals and labs in over 70 countries W ell experienced, strong and well retained R&
Slide 33: Our R&D Strengths
Our R&D Strengths Our well retained R&D team of scientific professionals including Ph.Ds. and M.Scs. brings vast experience in molecular diagnostics, assay design, and bioinformatics which reflects a stable, motivated workforce committed to scientific excellence and long-term innovation. This is
Slide 34: Comprehensive Panels for Syndromic Testing
Comprehensive Panels for Syndromic Testing The COVID-19 pandemic has underscored the importance of multiplex PCR TRUPCR® Flu Panel with RSV Detection Kit assays and syndromic diagnostic testing for infectious diseases, highlighting their utility in rapidly diagnosing and managing contagious illnesse
Slide 35: Antimicrobial Resistance – A Silent Pandemic
Antimicrobial Resistance – A Silent Pandemic Antimicrobial resistance (AMR) has become one of the most significant threats to public health worldwide, often referred to as the "silent pandemic" due to its gradual and insidious nature. Image Source: AMR Action Fund • Encouraging judicious use of anti
Slide 36: Solutions by 3B - to combat Antimicrobial Resistance
Solutions by 3B - to combat Antimicrobial Resistance We offer an extensive range of RT-PCR-based and lateral flow assays that demonstrates our proactive approach to addressing the global concern of antimicrobial resistance (AMR). TRUPCR® have both singlex and multiplexing RT-PCR assays for the detec
Slide 37: TRURAPID AMR Rapid Tests
Solutions by 3B - to combat Antimicrobial Resistance We are pleased to inform that we have successfully completed the collaborative R&D of the Rapid Tests for Anti- Microbial Resistance (AMR). The below assays have been launched to cater to the AMR segment: TRURAPID® RESIST-5 OKNVI Rapid Test (For
Slide 38: Next-Gen Sequencing (NGS) Vertical
Next-Gen Sequencing (NGS) Vertical We have started getting some traction for the TRUNGS® assays from the customers however, it is very low. The NGS market is at a very nascent stage and is divided in Whole Genome Sequencing, Whole Exome Sequencing, NIPT etc. With the TRUNGS® vertical, our main inten
Slide 39: Digital PCR
Digital PCR Our Research and Development (R&D) team is committed to the ongoing development of innovative products leveraging cutting-edge technologies. Through our dedication to scientific advancement and technological innovation, we strive to address emerging challenges and meet the evolving needs
Slide 40: Automated Extraction System
Automated Extraction System We are trying to offer automated extraction systems to our customers. Our team alongwith VGT’s team has invested considerable time and effort into identifying an automated extraction system that meets the growing needs of our customers. With this new addition, we are conf
Slide 41: Long Term Contracts
Long Term Contracts Signing long-term contracts with large customers is a strategic move that provides stability and predictability to the business operations. By securing commitments for 2-3 years, we can better forecast revenue streams and plan resources accordingly, reducing uncertainty and mitig
Slide 42: Utilization of Funds Existing & Utilized Capacity
Utilization of Funds During the last 2 years, we have evaluated several companies in the IVD space, however, the valuations were high due to demand from diagnostic companies based on Covid profits. Also, the Sales & EBITDA were not matching our IRR or future growth possibility, hence we did not proc
Slide 43: 3B for CSR
3B for CSR Army Wives Welfare Association or AWWA for short is an association that works for the welfare of the spouses, children and dependents of Army personnel. The aim of AWWA therefore is to support and augment the official welfare efforts within the Indian Army, focusing primarily on the wel-
Slide 44: 3B for CSR
3B for CSR Sightsavers is an international organisation that works in more than 30 countries to eliminate avoidable blindness, and fight for the rights & needs of people with disability. Sightsavers’ work in India has enabled thousands of people to lead lives of independence and dignity. “3B” has be
Slide 45: 3B for CSR
3B for CSR Prerna Sewa Trust, Bhopal, has been serving poor patients at Hamidia Hospital, Bhopal for decades through daily meals, free medicines, medical equipment, and support for treatment of serious ailments. In line with our CSR commitment, 3B has been supporting the Trust by funding medical aid
Slide 46: Recognitions & Awards
Recognitions & Awards Received the “Outstanding Received the “National Received the “Outstanding Achievement Award” in MSME Award – 2018” by Achievement Award” in recognition of excellence in Hon’ble President of India on recognition of excellence in R&D through technology by 11th May 2018 under MSM
Slide 47: JAI HIND
JAI HIND 2B BlackBio Dx Ltd.
3B BlackBio Dx — Investor Presentation (November 2025) on 6ix